Suggestions
Debanjan Ray
Chief Executive Officer at Synthekine
Debanjan Ray is a highly accomplished professional with a diverse background in the healthcare and biopharmaceutical industries.
He holds a Master of Business Administration (MBA) in Healthcare Management from The Wharton School and a Bachelor of Science (BS) in Chemical Engineering and Biology from the prestigious Massachusetts Institute of Technology (MIT).
Debanjan Ray has held key leadership positions in various organizations, demonstrating his expertise and strategic thinking.
He has served as the Chief Executive Officer at Synthekine, Chief Financial Officer, and Head of Corporate Development at CytomX Therapeutics, and Vice President of Business Development at Itero Biopharmaceuticals.
With a strong background in business development, Debanjan Ray has also worked at renowned companies such as Portola Pharmaceuticals and Genentech, where he contributed significantly as a Business Development professional.
Throughout his career, Debanjan Ray has showcased his analytical skills and business acumen in roles such as an Associate at JPMorgan Partners and a Business Analyst at McKinsey and Co.
His educational qualifications, combined with his extensive professional experience, make him a valuable asset in the healthcare and biopharmaceutical sectors.
Highlights
I'm excited to be kicking off another JPMorgan Healthcare Conference. 2023 was an incredibly productive year for Synthekine. Highlights include: advancing STK-012, our α/β biased IL-2 partial agonist, into cohort expansion studies; initiating dose escalation for STK-009 + SYNCAR-001, our cytokine enabled CD19 orthoCAR; and selecting a clinical candidate for STK-026, our T cell biased IL-12 partial agonist.
I'm proud to be presenting the progress at the conference on Wednesday, January 10, at 7:30am at the Westin St. Francis Golden Gate Room. Please join to learn more about Synthekine's accomplishments and our path to harnessing the potential of cytokines.
We have the audacious goal of building the category defining cytokine therapeutics company, advancing cytokine science along the way, and giving patients and physicians better options to treat cancer and autoimmune disease. A key part of that is having investors who share the same vision.
I am thrilled to welcome Deerfield Management, Janus Henderson Investors U.S., RA Capital Management, L.P., Rock Springs Capital, Omega Funds, TCG Crossover, and Lilly Asia Ventures 礼来亚洲基金 to Synthekine. A big thank you to The Column Group, Samsara BioCapital, Canaan, and Emerson Collective for getting the company to this point and your continued support of Synthekine.
https://lnkd.in/dTp6ZNB
Go Synthekine!
